Tag: Bydureon bcise

In 2022, prevalent use of GLP-1 receptor agonists like exenatide reached 27.1% among patients with type 2 diabetes and cardiovascular disease [1.7.1]. For those prescribed exenatide, understanding 'What is the difference between Bydureon and Bydureon BCise?' is key, as the delivery devices are vastly different.

In the management of type 2 diabetes, Bydureon BCise (exenatide) is a once-weekly injectable medication that helps control blood sugar [1.4.6]. A key question for patients is, **how long does it take for Bydureon BCise to work?** The answer involves both immediate and long-term effects.

As of late 2024, the manufacturer AstraZeneca has discontinued the production of both the original BYDUREON and its improved autoinjector version, BYDUREON BCise. The generic name for BYDUREON injection is **exenatide extended-release**, but no generic version is currently available on the market.

As of late 2024, the manufacturer AstraZeneca has formally discontinued all Bydureon products, including the popular Bydureon BCise auto-injector. For many people managing type 2 diabetes, this raises a critical question: Can you still get Bydureon? The definitive answer is no, and former users must now transition to a different therapy in consultation with their healthcare provider.